NO167386C - Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfider med anvendelse som immunmodulatorer. - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfider med anvendelse som immunmodulatorer.

Info

Publication number
NO167386C
NO167386C NO860907A NO860907A NO167386C NO 167386 C NO167386 C NO 167386C NO 860907 A NO860907 A NO 860907A NO 860907 A NO860907 A NO 860907A NO 167386 C NO167386 C NO 167386C
Authority
NO
Norway
Prior art keywords
sulphids
preparation
therapeutic active
immune modulators
analogy procedure
Prior art date
Application number
NO860907A
Other languages
English (en)
Norwegian (no)
Other versions
NO167386B (no
NO860907L (no
Inventor
Karl-Heinz Scheunemann
Walter Duerckheimer
Juergen Blumbach
Michael Limbert
Hans-Ulrich Schorlemmer
Gerhard Dickneite
Hans-Harald Sedlacek
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO860907L publication Critical patent/NO860907L/no
Publication of NO167386B publication Critical patent/NO167386B/no
Publication of NO167386C publication Critical patent/NO167386C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C07D277/74—Sulfur atoms substituted by carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO860907A 1985-03-12 1986-03-11 Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfider med anvendelse som immunmodulatorer. NO167386C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853508665 DE3508665A1 (de) 1985-03-12 1985-03-12 Heterocyclische sulfide und ihre anwendung als immunmodulatoren

Publications (3)

Publication Number Publication Date
NO860907L NO860907L (no) 1986-09-15
NO167386B NO167386B (no) 1991-07-22
NO167386C true NO167386C (no) 1991-10-30

Family

ID=6264870

Family Applications (1)

Application Number Title Priority Date Filing Date
NO860907A NO167386C (no) 1985-03-12 1986-03-11 Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfider med anvendelse som immunmodulatorer.

Country Status (21)

Country Link
US (1) US4762848A (xx)
EP (1) EP0194572B1 (xx)
JP (2) JPS61212590A (xx)
KR (1) KR940002255B1 (xx)
AR (1) AR247738A1 (xx)
AT (1) ATE70973T1 (xx)
AU (1) AU584993B2 (xx)
CA (1) CA1268769A (xx)
DE (2) DE3508665A1 (xx)
DK (1) DK165110C (xx)
ES (1) ES8801505A1 (xx)
FI (1) FI87203C (xx)
GR (1) GR860648B (xx)
HU (1) HU199441B (xx)
IE (1) IE58875B1 (xx)
IL (1) IL78090A (xx)
NO (1) NO167386C (xx)
NZ (1) NZ215425A (xx)
PH (1) PH24659A (xx)
PT (1) PT82167B (xx)
ZA (1) ZA861779B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047540A (en) * 1987-12-17 1991-09-10 Shionogi & Co., Ltd. Lipid derivatives
DE3816603A1 (de) * 1988-05-16 1989-11-30 Behringwerke Ag Verwendung des thiazol-derivates tiprotimod zur herstellung eines mittels zur therapie von virusinfektionen
DE3915094A1 (de) 1989-05-09 1991-01-10 Hoechst Ag Verfahren zur herstellung von 2-mercapto-4-methyl-1,3-thiazol-5-yl-essigsaeure und deren ester
TW252112B (xx) * 1993-08-19 1995-07-21 Pfizer
JP2001517666A (ja) * 1997-09-23 2001-10-09 藤沢薬品工業株式会社 チアゾール誘導体
CA2446136C (en) * 2001-05-03 2011-07-05 Galileo Pharmaceuticals, Inc. Pyruvate derivatives
TWI359810B (en) * 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
US8563746B2 (en) 2008-10-29 2013-10-22 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2022046625A1 (en) * 2020-08-26 2022-03-03 The Lubrizol Corporation 2,5-dimercapto-1,3,4-thiadiazole ("dmtd") metal salt derivatives

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR837278A (fr) * 1937-10-02 1939-02-07 Materiel Telephonique Dispositifs de sondage utilisant des ondes électro-magnétiques
US2776976A (en) * 1952-10-21 1957-01-08 Monsanto Chemicals Halogen substituted unsaturated thiazolylthioethers
US2886487A (en) * 1955-08-22 1959-05-12 Ortho Pharma Corp Quaternary ammonium salt and n-thiotrichloromethyl hydantoin vaginal composition
BE591151A (fr) * 1959-05-28 1960-11-23 Hoffmann La Roche Procédé pour la préparation de mono- et dihydrazino-triazines.
AT238200B (de) * 1962-03-27 1965-01-25 Degussa Verfahren zur Herstellung von neuen Pyridinderivaten
FR1509975A (fr) * 1965-10-21 1968-01-19 Geigy Ag J R Dérivés de l'imidazole et leur préparation
LU53029A1 (xx) * 1967-02-21 1968-08-27
US4139635A (en) * 1967-02-21 1979-02-13 L'oreal Cysteamine derivatives for oral treatment of seborrhea
US3950542A (en) * 1967-02-21 1976-04-13 L'oreal Cysteamine derivatives for oral treatment of seborrhea
US4035492A (en) * 1967-02-21 1977-07-12 L'oreal Oral treatment of seborrhea with cysteamine derivatives
FR7303M (xx) * 1967-03-07 1969-09-29
US3671643A (en) * 1969-09-15 1972-06-20 Oreal Treatment of excessive sebaceous glands secretion with substituted cysteamine compounds
DE2129012A1 (de) * 1971-06-11 1973-01-04 Merck Patent Gmbh Azol-derivate
DE2165554A1 (de) * 1971-12-30 1973-07-05 Bayer Ag Verfahren zur herstellung von 1,2,4triazin-5-on-derivaten
US3907822A (en) * 1973-06-11 1975-09-23 Squibb & Sons Inc Anti-inflammatory (2-benzimidazoylthio)alkylamidoximes
DE2359922A1 (de) * 1973-12-01 1975-06-05 Hoechst Ag (1-alkyl-5-nitro-imidazolyl-2-alkyl)- heteroaryl-verbindungen und verfahren zu ihrer herstellung
GB1462521A (en) * 1974-02-11 1977-01-26 Wyeth John & Brother Ltd Triazole derivatives
US4107438A (en) * 1974-09-30 1978-08-15 Victor Lafon Cyclic phenylsulphinyl-amidine derivatives
FR2285867A1 (fr) * 1974-09-30 1976-04-23 Lafon Labor Derives du diphenylsulfoxyde
US4022607A (en) * 1975-06-09 1977-05-10 Sandoz, Inc. Substituted oxazoles and thiazoles as herbicides
DE2533604A1 (de) * 1975-07-26 1977-02-10 Bayer Ag 2-substituierte 5-trifluormethyl1,3,4-thiadiazole, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide und insektizide
DK345676A (da) * 1975-07-31 1977-02-01 Wellcome Found Fremgangsmade til fremstilling af et oralt administrerbart farmaceutisk preparat
US4002624A (en) * 1976-01-26 1977-01-11 The Dow Chemical Company Substituted-3-thio-1,2,4-triazines
US4202901A (en) * 1976-03-04 1980-05-13 Ciba-Geigy Corporation 2-Pyridinecarbonitrile compounds
US4018923A (en) * 1976-03-10 1977-04-19 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents
FR2368278A1 (fr) * 1976-10-25 1978-05-19 Fabre Sa Pierre Nouveaux medicaments antalgiques contenant des triazines 1-2-4
US4182769A (en) * 1977-02-09 1980-01-08 E. I. Du Pont De Nemours And Company Anti-inflammatory 1-substituted-4,5-diaryl-2-(substituted-thio) imidazoles and their corresponding sulfoxides and sulfones
AT367296B (de) * 1977-04-12 1982-06-25 Ciba Geigy Ag Verfahren zur kurativen und prophylaktischen bekaempfung von parasitaeren helminthen
IL54474A (en) * 1977-04-12 1982-04-30 Ciba Geigy Ag Benzimidazole derivatives,their preparation and anthelmintic compositions containing them
GB1604084A (en) * 1977-05-17 1981-12-02 Diamond Shamrock Corp Pharmaceutical preparations containing 1,2,4-triazine derivatives
US4251527A (en) * 1977-05-17 1981-02-17 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines
US4157392A (en) * 1977-05-17 1979-06-05 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines
US4396625A (en) * 1980-05-13 1983-08-02 Sumitomo Chemical Company, Limited Treatment of glaucoma or ocular hypertension and ophthalmic composition
US4379159A (en) * 1980-10-16 1983-04-05 E. I. Du Pont De Nemours & Company Antiinflammatory 2-substituted-thio-4,5-dihydro-4,5-diaryl-1H-imidazoles
US4451471A (en) * 1981-03-18 1984-05-29 Ciba-Geigy Corporation Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same
DE3118126A1 (de) * 1981-05-07 1982-12-02 Bayer Ag, 5090 Leverkusen Sulfenamide zur verwendung in arzneimitteln
DE3216416A1 (de) * 1982-05-03 1983-11-03 Bayer Ag, 5090 Leverkusen Heteroarylthiovinyl-verbindungen, ein verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
DE3336846A1 (de) * 1983-10-11 1985-04-25 Bayer Ag, 5090 Leverkusen Neue 2-mercaptothiazolderivate, verfahren zu deren herstellung sowie die verwendung von 2-mercaptothiazolderivaten in arzneimitteln
ZA854550B (en) * 1984-06-18 1986-04-30 Smithkline Beckman Corp Leukotriene antagonists

Also Published As

Publication number Publication date
AU5460686A (en) 1986-10-16
IE58875B1 (en) 1993-12-01
DK108686D0 (da) 1986-03-10
PT82167B (pt) 1988-07-29
FI87203C (fi) 1992-12-10
DK165110B (da) 1992-10-12
GR860648B (en) 1986-07-11
DE3508665A1 (de) 1986-09-18
NO167386B (no) 1991-07-22
AU584993B2 (en) 1989-06-08
FI860981A (fi) 1986-09-13
PH24659A (en) 1990-09-07
DE3683172D1 (de) 1992-02-13
FI860981A0 (fi) 1986-03-10
JPH0380792B2 (xx) 1991-12-26
AR247738A1 (es) 1995-03-31
IE860631L (en) 1986-09-12
IL78090A0 (en) 1986-07-31
DK108686A (da) 1986-09-13
KR860007235A (ko) 1986-10-10
HU199441B (en) 1990-02-28
IL78090A (en) 1991-08-16
ES8801505A1 (es) 1988-01-16
ES552841A0 (es) 1988-01-16
JPS6452719A (en) 1989-02-28
CA1268769A (en) 1990-05-08
NZ215425A (en) 1990-01-29
KR940002255B1 (ko) 1994-03-19
DK165110C (da) 1993-03-01
EP0194572B1 (de) 1992-01-02
HUT44524A (en) 1988-03-28
JPS61212590A (ja) 1986-09-20
ZA861779B (en) 1986-10-29
NO860907L (no) 1986-09-15
FI87203B (fi) 1992-08-31
EP0194572A1 (de) 1986-09-17
PT82167A (de) 1986-04-01
ATE70973T1 (de) 1992-01-15
US4762848A (en) 1988-08-09

Similar Documents

Publication Publication Date Title
NO163406C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazokinolinonderivater.
NO862477D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-arylimidazol-derivater.
NO167384C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-aralkylpiperidinmethanolderivater.
NO864126D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyridon-derivater.
NO871267L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tiazepinforbindelser.
NO166639C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte, basiske 2-aminotetraliner.
NO164165C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminotetralinderivater.
NO162514C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinonderivater.
NO874869D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
NO864879L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tiazolforbindelser.
NO864674D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive cefemforbindelser.
NO166080C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5,6,8-trifluorkinoliner.
NO167026C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
NO862373D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tienopyridoner.
NO161562C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive ergolinderivater.
NO870049L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO161559C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive triazolderivater.
NO863373L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO164897C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive oxazolidinonderivater.
NO158941C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-piperidino-kinazolinderivater.
NO167386C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfider med anvendelse som immunmodulatorer.
NO862372D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater.
NO165069C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cyklopentyletere.
NO166130C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-pyridonderivater.
NO873835D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive karbocykliske pyridiner.